Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review
Min Huang, Amin Haiderali, Grace E. Fox, et al.
PharmacoEconomics (2022) Vol. 40, Iss. 5, pp. 519-558
Open Access | Times Cited: 25

Showing 25 citing articles:

Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies
Nating Xiong, Heming Wu, Zhikang Yu
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 21
Synergistic effects of photodynamic therapy and chemotherapy: Activating the intrinsic/extrinsic apoptotic pathway of anoikis for triple-negative breast cancer treatment
Tianyu Zhang, Xueyuan Wang, Dongna Wang, et al.
Biomaterials Advances (2024) Vol. 160, pp. 213859-213859
Closed Access | Times Cited: 8
Assessing the clinical, humanistic, and economic impact of early cancer diagnosis: a systematic literature review
R. Aguiar-Ibáñez, Yves Paul Vincent Mbous, Sheetal Sharma, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
RNA-lipid nanoparticle therapeutics for women’s health
Alireza Nomani, Aishwarya Saraswat, Yu Zhang, et al.
Frontiers in Nanotechnology (2025) Vol. 7
Open Access
Updates on Triple-Negative Breast Cancer in Type 2 Diabetes Mellitus Patients: From Risk Factors to Diagnosis, Biomarkers and Therapy
Sabine Matou‐Nasri, M Sarawatense Aldawood, Fatimah Alanazi, et al.
Diagnostics (2023) Vol. 13, Iss. 14, pp. 2390-2390
Open Access | Times Cited: 11
Manufacturing and Financial Evaluation of Peptide-Based Neoantigen Cancer Vaccines for Triple-Negative Breast Cancer in the United Kingdom: Opportunities and Challenges
Alena Nováková, Stephen Morris, Ludovica Vaiarelli, et al.
Vaccines (2025) Vol. 13, Iss. 2, pp. 144-144
Open Access
Burden of Disease and Cost of Illness of Triple-Negative Breast Cancer in Portugal
Joana Silva, Gabriela Sousa, Luís Teixeira da Costa, et al.
PharmacoEconomics - Open (2025)
Open Access
Triple-Negative Breast Cancer Systemic Treatment: Disruptive Early-Stage Developments for Overcoming Stagnation in the Advanced Pipeline
Carlos Alonso-Ron, Andrea Vethencourt, Eva González‐Suárez, et al.
Cancers (2025) Vol. 17, Iss. 4, pp. 633-633
Open Access
Overall Survival and Economic Impact of Triple-Negative Breast Cancer in Brazilian Public Health Care: A Real-World Study
André Mattar, Marcelo Antonini, Andressa Gonçalves Amorim, et al.
JCO Global Oncology (2025), Iss. 11
Open Access
A US Survey Across Seven Early-Stage Cancers Assessing the Humanistic Burden of Recurrence on Patients and Caregivers
R. Aguiar-Ibáñez, Kelly McQuarrie, Ana Martinez, et al.
Oncology and Therapy (2025)
Open Access
Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355
David W. Cescon, Peter Schmid, Hope S. Rugo, et al.
JNCI Journal of the National Cancer Institute (2023) Vol. 116, Iss. 5, pp. 717-727
Closed Access | Times Cited: 7
A systemmatic literature review on indirect costs of women with breast cancer
Saeed Mohammadpour, Samira Soleimanpour, Javad Javan‐Noughabi, et al.
Cost Effectiveness and Resource Allocation (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 11
Bibliometric analysis of global research on physical activity and sedentary behavior in the context of cancer
Jialin Gu, Miao Hu, Yonglin Chen, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 5
Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study
Peter Schmid, O. N. Lipatov, Seock‐Ah Im, et al.
European Journal of Cancer (2023) Vol. 195, pp. 113393-113393
Closed Access | Times Cited: 5
Cost-Effectiveness of Neoadjuvant Pembrolizumab plus Chemotherapy Followed by Adjuvant Pembrolizumab in Patients with High-Risk, Early-Stage, Triple-Negative Breast Cancer in Switzerland
Andrea Favre-Bulle, Min Huang, Amin Haiderali, et al.
PharmacoEconomics - Open (2023) Vol. 8, Iss. 1, pp. 91-101
Open Access | Times Cited: 5
Modulatory Effects of XIAOPI Formula on CXCL1 and Selected Outcomes in Triple-Negative Breast Cancer: A Randomized Controlled Clinical Trial
Li Guo, Shicui Hong, Xuan Wang, et al.
Breast Cancer Targets and Therapy (2024) Vol. Volume 16, pp. 289-303
Open Access | Times Cited: 1
A Narrative Review of the Clinical, Humanistic, and Economic Value of Pembrolizumab-Based Immunotherapy for the Treatment of Breast and Gynecologic Cancers
Matthew Monberg, Steve Keefe, Vassiliki Karantza, et al.
Oncology and Therapy (2024)
Open Access | Times Cited: 1
Impact of recurrence on employment, finances, and productivity for early-stage cancer patients and caregivers: US survey
R. Aguiar-Ibáñez, Kelly McQuarrie, Sayeli Jayade, et al.
Future Oncology (2024), pp. 1-17
Open Access | Times Cited: 1
Pharmacoeconomics of novel pharmacotherapies in triple-negative breast cancer
Luca Boscolo Bielo, Dario Trapani, Giuseppe Curigliano
Expert Opinion on Pharmacotherapy (2023) Vol. 24, Iss. 7, pp. 789-801
Open Access | Times Cited: 3
Triple-negativer Brustkrebs: Mit Pembrolizumab die Lebensqualität im metastasierten Stadium verbessern
Brigitte Sophia Winkler
Kompass Onkologie (2024) Vol. 11, Iss. 2, pp. 80-81
Closed Access
Assessing the fiscal consequences of novel and existing treatments for triple negative breast cancer in Switzerland by applying a government perspective framework
Cillian Copeland, Nikolaos Kotsopoulos, Andrea Favre-Bulle, et al.
Journal of Medical Economics (2024) Vol. 27, Iss. 1, pp. 858-865
Open Access
Economic assessment of abemaciclib for the adjuvant treatment of luminal HER2- breast cancer from the perspective of the Spanish health system
S Fénix-Caballero, Adrián Sánchez-Vegas, Emilio Jesús Alegre Del Rey, et al.
The European Journal of Health Economics (2024)
Closed Access
Deciphering the miRNA–mRNA Interaction Landscape between Breast Cancer and Triple-Negative Breast Cancer: An Integrated Bioinformatics Approach
Ambritha Balasundaram, Tanisha Saurav Mitra, Iftikhar Aslam Tayubi, et al.
ACS Omega (2024) Vol. 9, Iss. 23, pp. 24379-24395
Open Access
Low-intensity pulsed ultrasound combined with microbubble mediated JNK/c-Jun pathway to reverse multidrug resistance in triple-negative breast cancer
Nina Qu, Zhihui Wu, Qingkai Meng, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access
Breast Cancer and Income Loss in Denmark: Heterogeneous Outcomes and Longitudinal Effects
Emily Johnson, Harsh Parikh, Kim Rose Olsen, et al.
Research Square (Research Square) (2024)
Closed Access
Page 1

Scroll to top